POSA117 Cost-Effectiveness Analysis of Third-Line Pazopanib Versus Regorafenib for Metastatic or Unresectable Gastrointestinal Stromal Tumors in China

Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.260
https://www.valueinhealthjournal.com/article/S1098-3015(21)02055-6/fulltext
Title : POSA117 Cost-Effectiveness Analysis of Third-Line Pazopanib Versus Regorafenib for Metastatic or Unresectable Gastrointestinal Stromal Tumors in China
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02055-6&doi=10.1016/j.jval.2021.11.260
First page :
Section Title :
Open access? : No
Section Order : 11034
Categories :
Tags :
Regions :
ViH Article Tags :